Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

Kruspe, Sven; Giangrande, Paloma H.

doi:10.3390/biomedicines5030045

Cited by 71 publications

(56 citation statements)

References 127 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a disproportionately large number of publications and patents describing aptamer applications compared to the number of publications describing new aptamers [ 79 ]. This trend is consistent across most areas of aptamer research including food safety [ 80 ], neuroscience [ 81 ], medicine [ 82 ] and gene control [ 83 ]. In contrast, the opposite appears to be true in the field of DNA damage and repair; there are fewer examples of aptamer applications compared to the number of selections ( Table 1 ).…”

Section: Promising Applicationssupporting

confidence: 56%

Aptamers for DNA Damage and Repair

McKeague

2017

IJMS

View full text Add to dashboard Cite

DNA is damaged on a daily basis, which can lead to heritable mutations and the activation of proto-oncogenes. Therefore, DNA damage and repair are critical risk factors in cancer, aging and disease, and are the underlying bases of most frontline cancer therapies. Much of our current understanding of the mechanisms that maintain DNA integrity has been obtained using antibody-based assays. The oligonucleotide equivalents of antibodies, known as aptamers, have emerged as potential molecular recognition rivals. Aptamers possess several ideal properties including chemical stability, in vitro selection and lack of batch-to-batch variability. These properties have motivated the incorporation of aptamers into a wide variety of analytical, diagnostic, research and therapeutic applications. However, their use in DNA repair studies and DNA damage therapies is surprisingly un-tapped. This review presents an overview of the progress in selecting and applying aptamers for DNA damage and repair research.

show abstract

Section: Promising Applicationssupporting

confidence: 56%

Aptamers for DNA Damage and Repair

McKeague

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…The therapeutic superiority of aptamer-RNA chimeras has been demonstrated in recent years. 56 Wang et al constructed an aptamer-siRNA chimera targeted to epithelial cell adhesion molecule and survivin to deliver a high dose of siRNA and silence resistance to doxorubicin. 57 Silencing of survivin (a key protein involved in drug resistance) resulted in a significant reversal of chemoresistance.…”

Section: Drug Potentiation Via Aptamer Modificationmentioning

confidence: 99%

<p>Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications</p>

Guan¹,

Zhang²

2020

IJN

View full text Add to dashboard Cite

Aptamers are a class of targeting ligands that bind exclusively to biomarkers of interest. Aptamers have been identified as candidates for the construction of various smart systems for therapy, diagnosis, bioimaging, and drug delivery due to their high target affinity and specificity. Aptamers are accounted as chemical antibodies that can be readily linked to drugs, sensors, signal enhancers, or nanocarriers for functionalization. Use of aptamer-guided medications, especially nanomedicines, has resulted in encouraging outcomes compared to those use of aptamer-free counterparts. This article reviews recent advances in the use of aptamers as targeting ligands for various biomedical and pharmaceutical purposes. Special interests focus on aptamer-based theranostics, biosensing, bioimaging, drug potentiation, and targeted drug delivery.

show abstract

“…The idea of a tailored drug for the treatment of a diseased cell avoiding affecting the surrounding healthy cells is not recent, as recalled by Kruspe and Giangrande [54]. It was initially proposed by Paul Ehrlich about one century ago, when he first defined the "magic bullet" and its inherent concept of cell-surface receptor [55].…”

Section: Tumor-targeted Aptamers Complexed Directly To Sirnas and Othmentioning

confidence: 99%

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer

Almeida

et al. 2019

Pharmaceutics

View full text Add to dashboard Cite

Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in combination with siRNAs, in the form of specific delivery agents. This combination offers the potential to explore the high affinity and specificity of aptamers, the silencing power of siRNA, and, at times, the cytotoxicity of chemotherapy molecules in powerful combinations that promise to delivery new and potent therapies. In this review, we report new developments in the field, following up from our previous work, more specifically on the use of aptamers as delivery agents of siRNA in nanoparticle formulations, alone or in combination with chemotherapy, for the treatment of cancer.

show abstract

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

Cited by 71 publications

References 127 publications

Aptamers for DNA Damage and Repair

Aptamers for DNA Damage and Repair

<p>Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications</p>

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer

Contact Info

Product

Resources

About